BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2023 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on October 31, 2023.

Congruence Therapeutics, a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecule correctors for disease, announced today that it will participate in the 3rd Annual Needham Private Biotech Company Virtual 1x1 Forum, taking place October 17-18, 2023.

Mirum Pharmaceuticals, Inc. announced that on October 10, 2023, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 92,050 shares of common stock and 46,030 restricted stock units to 12 new employees under Mirum’s 2020 Inducement Plan.

Genentech, a member of the Roche Group, announced positive topline long-term results from the global Phase III BALATON and COMINO studies evaluating extended treatment intervals with Vabysmo® in macular edema due to branch and central retinal vein occlusion.

AstriVax is pleased to announce that Dr. Mathieu Peeters and Barbara Freitag have joined the company’s leadership team as Chief Development Officer and Chief Financial Officer, respectively.

RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, announced that over 400,000 of its ADRs are now outstanding.

XNK Therapeutics AB announced that it has applied for and been granted funding by Sweden’s innovation agency Vinnova.

EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, announced the presentation of new analyses from the MAVENCLAD® tablets MAGNIFY-MS study, which demonstrated that patients with relapsing multiple sclerosis experienced sustained reduction in serum neurofilament light chain, indicating that MAVENCLAD reduced neuronal injury over two years.

Sosei Group Corporation and PharmEnable Therapeutics, a UK drug discovery company, announce they have expanded their collaboration to apply their respective technologies to drive novel drug discovery for a second neurological disease target.

GPCR Therapeutics, Inc., a clinical-stage, international biopharmaceutical company, announced the expansion of its pipeline into fibrosis with the publication of a paper in Cell Communication and Signaling.